ABSTRACT. BALB/cByJ (J) mice have short-chain acylCoA dehydrogenase (SCAD) deficiency and an organic aciduria similar to that of human SCAD deficiency.
' Present address: Department of Microbiology, University of lowa, lowa City, IA. analyses in fibroblasts revealed an isolated, specific SCAD deficiency (1,2). SCAD catalyzes the first reaction in the 0-oxidation of short-chain fatty acids. It is a 160-kD tetrameric mitochondria1 flavoprotein, with subunits of 4 1 kD (3,4). SCAD is synthesized in the cytoplasm as a 44-kD precursor and is processed in the mitochondrion to the 41-kD active form (5) .
To identify animal models for human metabolic diseases, Wood et al. (6) screened mice systematically for inherited metabolic defects. During these studies, they discovered a subline of BALB/c mice (BALB/cByJ) that excreted abnormally high concentrations of ethylmalonate, methylsuccinate, n-butyrylglycine, and n-butyrylcarnitine (7) . These metabolites suggested a defect in short-chain acyl-CoA dehydrogenation, inasmuch as all can be formed intramitochondrially from accumulated butyryl-CoA (1, 2, 7). Other investigators reported previously that this substrain has a null allele for butyryl-CoA dehydrogenase activity (bcd-1 locus), a genetic marker on mouse chromosome 5 (8) . In this report, we describe the enzymatic defect and absence of SCAD antigen and biosynthesis in multiple tissues from these BALB/cByJ (J) mutant mice. Although Turnbull et a/. (9) and Farnsworth et al. (10) reported a human patient with apparent muscular SCAD deficiency, our observations argue against the presence of tissue-specific SCAD isoforms in mammals.
MATERIALS AND METHODS
Materials. [9, 10( Pure pig kidney MCAD and pig liver SCAD for antisera preparation and electron transfer flavoprotein were gifts from Drs. Colin Thorpe (1 1) (University of Delaware, Newark, DE) and Carole Hall (1 2) (Georgia Institute of Technology, Atlanta, GA). Polyclonal monospecific antisera against purified SCAD and MCAD were prepared as previously described (1).
Mice. BALB/cBy and BALB/cByJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and propagated at the Baylor College of Medicine (Houston, TX). All mice were maintained on Wayne rodent food number 8640 (Wayne Pet Food Division, Continental Grain Co., Chicago, IL) and water a d libitum.
Preparation of fibroblasts. Ear skin was obtained aseptically and rinsed in a-minimal essential medium (a-MEM; Sigma Chemical Co.). The skin was washed with 1 mL of a-MEM containing 1 mg/mL collagenase without FCS (Hazleton, Lenexa, KS) supplemented with 140 WM penicillin and 86 WM streptomycin. The ear skin was minced, placed in 1.5 mL of collagenase solution, and incubated at 37°C for 3 h, then centri-fuged at 800 x g for 5 min. The supernatant was discarded and the pelleted cells resuspended in 5 mL of a-MEM, supplemented with 10% FCS and penicillin/streptomycin, and then seeded into culture flasks. Fibroblasts were subcultured 1:4 every 2 wk, with the media changed weekly. Fibroblasts of passage 6 to 20 were used in all experiments.
3H-palmitate oxidations and enzymatic analyses. [9,10( Immunoprecipitation studies. These studies were performed as described by Ikeda et al. (5) . Fibroblast monolayers in 25 cm2 flasks were labeled with [35S]methionine (60 pCi/mL) in methionine-free RPMI 1640 for 12 h and then solubilized in 10 mM EDTA, 0.5% Triton X-100, 0.25% SDS, 2% methionine and 150 mM NaC1, pH 7.2. The extracts were immunoprecipitated by 10 pL of rabbit anti-pig SCAD antiserum or by 10 pL of preimmune antiserum using heat-killed formalin-fixed Staphylococcus aureus cells (Boehringer-Mannheim, Indianapolis, IN).
The immunoprecipitates were analyzed by 10% SDS-PAGE and revealed by fluorography. In competition experiments, 10 pg of unlabeled pig liver SCAD was added before antiserum addition. MCAD immunoprecipitation studies were performed identically to the SCAD studies, except that the extracts were immunoprecipitated with 10 pL rabbit anti-pig MCAD antiserum, and 5 pg unlabeled pig liver MCAD was added in the competition experiments.
RESULTS

Fibroblast catabolism of tritiated palmitates.
Fibroblasts from J mutant mice oxidized [9, lO(n)-'Hlpalmitate to 'HzO normally at 96% of control, whereas [15, 16(n)-3H]palmitate oxidation was significantly decreased at only 35% of control (Table I) . The residual oxidation noted with the former substrate is comparable to that found in human SCAD-deficient fibroblasts (1 3).
Mouse tissue mitochondrial acyl-CoA dehydrogenase activities.
Our earlier studies in control mouse liver showed that about half of butyryl-CoA dehydrogenation was due to MCAD and half to SCAD under our assay conditions. In the present study, we evaluated the relative contribution of SCAD and MCAD to butyryl-CoA dehydrogenation in two additional tissues: skeletal *The Y control mice are BALB/cBy and the mutant J mice are BALB/cByJ. The mice were 1 mo old and mitochondria were isolated from muscle as described in Materials and Methods (15) and from fibroblasts as described earlier (I). Antiserum to rabbit anti-pig kidney MCAD (10 pL) was used as previously described (1). Values are pmol/ minlmg protein 5 S.D. muscle and fibroblasts (Table 2 ). In muscle mitochondria from J mice, butyryl-CoA dehydrogenation was 82% of that in Y mice, suggesting that MCAD contributes a greater proportion of activity toward butyryl-CoA in muscle than in liver. However, in the presence of monospecific MCAD antiserum, the J mice had absent SCAD activity with butyryl-CoA, with a similar change in MCAD-catalyzed butyryl-CoA dehydrogenation in both Y and J mice. In fibroblasts from J mice. butyryl-CoA dehydrogenation was 69% of that in Y cells, suggesting that the contribution of MCAD to butyryl-CoA dehydrogenation differs in fibroblasts. Upon addition of MCAD antiserum, butyryl-CoA dehydrogenation was absent in J mice cells, and both Y and J mice had comparable changes in MCAD activity toward butyrylCoA. There was no contribution of SCAD to apparent octanoylCoA dehydrogenation in either tissue, inasmuch as MCAD activity with octanoyl-CoA was identical in both J and Y mice and completely inhibited by MCAD antiserum. undetectable in J mouse muscle mitochondria, but Y mice had easily detectable levels. As in liver, mouse muscle SCAD had a mobility identical to that of pig liver SCAD (data available on request). Fibroblast mitochondria from J mice also had no SCAD antigen ( Fig. 2A, lanes 3 and 4) , whereas SCAD antigen was easily detectable in Y mice (Fig. 2, lanes I and 2) , even after applying 2-to 3-fold more mitochondria1 protein from J than from Y mice. Again, MCAD antigen was present in both Y and J mouse fibroblast mitochondria (Fig. 2B) .
Incubation of fibroblast monolayers with [35S]methionine for
12 h followed by immunoprecipitation with antisera against either SCAD or MCAD revealed no newly synthesized SCAD polypeptide in J fibroblasts (Fig. 3A, lanes 1 and 4) , whereas MCAD was synthesized comparably in both Y and J cells (Fig.  3B, lanes 1 and 4) . Competition experiments with unlabeled antigens confirmed the identities of the newly synthesized polyt Sum of SCAD and MCAD activities toward toward butyryl-CoA.
$ Represents only SCAD activity toward butyryl-CoA. The V,,, of J mutants toward butyryl-CoA reflects only MCAD activity toward butyryl-CoA, whereas this value in the Y controls equals the sum of the V,,, of SCAD and MCAD toward butyryl-CoA, as predicted. The apparent Km of MCAD toward octanoyl-CoA, its optimal substrate, is 1.2 and 1.1 pM in Y and J mice, respectively, similar to those of MCAD from other species (3,4, 1 1, 12) . In all mice, these similar V, , , values reflect only MCAD activity toward octanoyl-CoA, because SCAD has no activity toward this substrate in mouse, rat, or human liver (3, 4).
Imrnunochemical studies of SCAD and MCAD.
Immunoblot analysis of mouse liver revealed no SCAD antigen in three J mice (Fig. lA, lanes 5, 6, and 7) , whereas three Y mice had easily detectable levels (Fig. lA, lanes 1, 2, and 3) . MCAD antigen was present in comparable amounts in both Y and J mice (Fig. 1B) . Both SCAD and MCAD from mouse liver mitochondria migrated identically to their purified porcine counterparts, suggesting that their mature molecular weights are similar to those reported in other mammals (3, 4, 1 1 ) . SCAD antigen was also pg protein, respectively; lanes 3 and 4. J mutants, 620 and 3 10 pg protein, respectively. 3 and 6 ) using S. uureus cells. The immunoprecipitates were analyzed by SDS-PAGE and revealed by fluorography. Lanes 2 and 5 are identical to lunes 1 and 4, respectively, except that 10 pg of unlabeled pig liver SCAD were added before antiserum addition (competition experiment). B, As in A, except that the extracts were immunoprecipitated with rabbit anti-pig MCAD antiserum and 5 pg of unlabeled pig liver MCAD were added in lanes 2 and 5.
peptides as SCAD and MCAD (Fig. 3A and B, lanes 2 and 5 ) , Tissue-specific differences in the ratio of SCAD to MCAD whereas preimmune serum did not coprecipitate any radiola-activities and the kinetic properties of mouse SCAD may help beled species (Fig. 3A and B, lanes 3 and 6) .
explain the mild disease noted in the mutant mice. Under our assay conditions, MCAD activity in mouse muscle toward bu-DISCUSSION tyryl-CoA appears higher than that in either mouse liver, mouse fibroblasts, or human fibroblasts, representing 82% of total buBoth SCAD-deficient mice and humans share similiar clinical tyryl-CoA dehydrogenation activity in this tissue. The increased characteristics, including a tendency toward hypoglycemia, he-MCAD activity toward but~ryl-CoA in muscle may explain the patic lipid deposition, and similar organic acidurias (1, 2, 6 ). In lack of clinical symptoms in the J mouse, inasmuch as total body man, SCAD deficiency causes the accumulation and excretion short-chain ac~l-CoA dehydrogenation could be largely catalyzed of short-chain acyl-CoA metabolites, such as ethylmalonate, by muscle MCAD. Unfortunately, there are no objective measadipate, and methylsuccinate (1, 2). The BALB/cByJ mice also ures of total body short-or medium-chain fatty acid oxidation excrete ethylmalonic and methylsuccinic acids, as well as large flux in control or mutant mice to test this hypothesis. Comparing amounts of n-butyrylglycine and n-butyrylcarnitine, which are the kinetic parameters of mouse liver SCAD and MCAD to the not prominent in human patients (1, 2). This probably results published values for the corresponding human liver enzymes from differences between rodents and humans in glycine conju-reveals that the Km of purified human liver MCAD toward gation of various acyl-CoA derivatives, particularly butyryl-CoA but~ryl-CoA is 7 1.4 PM (4), 2-fold higher than the apparent Km (19) . Butyrylglycine excretion in the mouse is analogous to the of mouse liver m i t~~h o n d r i a l MCAD toward but~ryl-CoA. This isovalerylglycine excretion found in the human disease, isovaleric lowered Km (or increased affinity) of mouse liver MCAD for acidemia, due to isovaleryl-CoA dehydrogenase deficiency (20) . but~ryl-CoA might also help explain the mild overall impairment In the mouse, the increased flux of butyryl-CoA through this of butyryl-COA dehydrogenation flux noted in the SCAD-defidetoxification pathway may explain their relative resistance to cient mice (7) . acute clinical disease. This increased capacity for &cine conju-
The absence of SCAD antigen in liver, muscle, and fibroblasts gation of butyryl-CoA may also reduce intramitochondrial acyl-from the mutant mouse also argues against the existence of CoA concentrations, preserving the intracellular carnitine pool tissue-specific SCAD isoz~mes in n~ammals. However, in the and maintaining normal mitochondria1 acyl-CoA/reduced COA human SCAD-deficient patients, SCAD antigen levels varied. ratios.
Only one SCAD-deficient patient had no detectable SCAD anFibroblasts from both SCAD-deficient humans (1) and mice tigen on direct immunoblotting of fibroblasts, whereas the other oxidize short-chain fatty acids poorly. J mouse fibroblasts oxi-two had normal amounts of mrmal molecular weight antigen dized [9, 10(n)-3H]palmitate normally, but [15,16( (25) . In biosynthesis and immunoprecipitation experiments, all tate poorly, as did SCAD-deficient human fibroblasts (1 3, 2 1). three patients had ~-~ormal amounts of newly synthesized enzyme Because [15,16(n) -3H]palmitate is converted to [3,4(n)-3H]butyr-polypeptide; thus, .!XAD in the first patient may be extremely ate after seven successive rounds of P-oxidation, oxidation of labile and rapidly degraded (25, 26) . The synthesis and size of and tritiated water formation from this substrate require SCAD SCAD mRNA in three SCAD-deficient patients were also normal activity. Because the C4-C6 acyl-CoA derived from [9,1 0(n)-3H]- (23) . These results suggested that the SCAD defects in man are palmitate are unlabeled, its oxidation should be normal in caused by at least two different point mutations, a suspicion that SCAD-deficient cells. The [15,16(n) -3H]palmitate oxidation in J has been recently confirmed (27) . In contrast, our data suggest mice is somewhat lower (35% of control) than might be predicted that SCAD gene structure, transcription, or translation is Profrom the observed butyryl-CoA dehydrogenation activities in the foundly altered in the mutant J mice. The SCAD-deficient mouse mutant mice tissues ( 4 4 4 2 % of control). However, the observed probably has a mutation at or near the Bed-1 locus on chromaoxidation rates of the 3H-palmitates in intact fibroblasts may not some 5, such that either the mRNA or polypeptide is not yield valid estimates of tissue or total body o-oxidation flux. synthesized or is extremely unstable. Preliminary molecular studThese intact fibroblast studies permit rapid identification of ies suggest that there is a deletion in the 5' region of the SCAD SCAD deficiency in both man and mouse, simplifying detection gene in the mutant mice (28) . Further experiments are undernay of this disorder and its differentiation from those P-oxidation to elucidate more precisely this molecular defect. disorders impairing medium-and long-chain fatty acid oxidaThese results reflect both the advantages and the limitations tion.
of studying animal models of human metabolic diseases. Species In SCAD-deficient mice, liver, muscle, and fibroblast SCAD differences in alternative metabolic or detoxification pathways, and MCAD activities were qualitatively similar to those reported enzyme activities, and substrate affinities may yield significant in human SCAD deficiency (1, 2). Human liver SCAD and variations in clinical, metabolic and biochemical phenotypes. MCAD are identical in electrophoretic mobility and molecular However, animal models permit a breadth and depth of expenweight to those in human fibroblasts and closely resemble their mentation clearly impossible with the vast majority of human rat liver counterparts (3, 4, 22, 23). However, Turnbull et al. (9) Patients and disorders.
and Farnsworth et al. (10) reported an adult patient with an isolated muscular deficiency of SCAD activity and antigen. A
